Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Financial Officer | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 321,992 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Exercise / conversion · Acquired 61,378 · Balance 321,992 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F2: This number includes 373 shares acquired under the Registrant's employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 320,492 |
Reported balance
After 2026-06-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-30 · Sale · Disposed 1,500 · Balance 320,492 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 318,792 |
Reported balance
After 2026-06-30 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-06-30 · Sale · Disposed 1,700 · Balance 318,792 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 317,692 |
Reported balance
After 2026-06-30 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-06-30 · Sale · Disposed 1,100 · Balance 317,692 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 313,582 |
Reported balance
After 2026-06-30 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-06-30 · Sale · Disposed 4,110 · Balance 313,582 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 262,207 |
Reported balance
After 2026-06-30 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-06-30 · Sale · Disposed 51,375 · Balance 262,207 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 254,236 |
Reported balance
After 2026-06-30 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2026-06-30 · Sale · Disposed 7,971 · Balance 254,236 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 248,083 |
Reported balance
After 2026-06-30 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2026-06-30 · Sale · Disposed 6,153 · Balance 248,083 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 244,883 |
Reported balance
After 2026-06-30 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2026-06-30 · Sale · Disposed 3,200 · Balance 244,883 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.33 · Expires 2030-05-13 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-30 · Exercise / conversion · Disposed 61,378 · Balance 0 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F11: The shares underlying this stock option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person.
F2: This number includes 373 shares acquired under the Registrant's employee stock purchase plan.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11: The shares underlying this stock option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,378 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · derivative · entry 10 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,378 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F11 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,200 | $117.70 | $376,649.28 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 9 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,883 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,153 | $116.99 | $719,862.24 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 8 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,083 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,971 | $115.82 | $923,178.10 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 7 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 254,236 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 51,375 | $114.77 | $5,896,288.20 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 6 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,207 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,110 | $114.19 | $469,310.63 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,582 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,100 | $112.79 | $124,066.91 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,692 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,700 | $111.57 | $189,664.07 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 318,792 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,500 | $110.54 | $165,809.55 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 320,492 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 61,378 | $5.33 | $327,144.74 |
DisclosureSEC source: 0001193125-26-295090 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person. F2 · balance_after: This number includes 373 shares acquired under the Registrant's employee stock purchase plan. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 11:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,653 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-26-254589 · ownership.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,653 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 11:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 12,653 | $2.08 | $26,318.24 |
DisclosureSEC source: 0001193125-26-254589 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2026 Filed May 19, 2026 11:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-26-229656 · ownership.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,653 Underlying: Common Stock · 15,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| May 18, 2026 Filed May 19, 2026 11:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0001193125-26-229656 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 447 | $86.62 | $38,721.24 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · nonDerivative · entry 8 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,588 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,437 | $85.78 | $123,266.87 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · nonDerivative · entry 7 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,035 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,519 | $85.04 | $214,206.69 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · nonDerivative · entry 6 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,472 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 492 | $84.00 | $41,326.28 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · nonDerivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,991 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 35,300 | $0.00 Strike: $90.10 | $0.00 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · derivative · entry 9 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,300 Underlying: Common Stock · 35,300 shares Expires 2036-03-01 F10 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,113 | $89.66 | $368,760.89 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,483 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,424 | $88.50 | $126,024.57 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,596 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,039 | $87.75 | $178,924.09 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,020 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 17,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-091982 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,059 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 17, 2025 Filed Sep 17, 2025 21:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,974 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-25-206350 · ownership.xml · derivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,974 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| September 17, 2025 Filed Sep 17, 2025 21:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,246 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-25-206350 · ownership.xml · derivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,653 Underlying: Common Stock · 42,246 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| September 17, 2025 Filed Sep 17, 2025 21:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 79,220 | $50.00 | $3,961,380.26 |
DisclosureSEC source: 0001193125-25-206350 · ownership.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,409 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.90 to $50.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2025 Filed Sep 17, 2025 21:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 79,220 | $2.08 | $164,777.60 |
DisclosureSEC source: 0001193125-25-206350 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F2 · balance_after: This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 12:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-25-048049 · ownership.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,899 Underlying: Common Stock · 25,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares vested in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 12:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 25,000 | $2.08 | $52,000.00 |
DisclosureSEC source: 0000950170-25-048049 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0000950170-25-031146 · ownership.xml · derivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-03-02 F5 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,281 | $31.00 | $39,716.89 |
DisclosureSEC source: 0000950170-25-031146 · ownership.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,886 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,754 | $30.33 | $174,502.13 |
DisclosureSEC source: 0000950170-25-031146 · ownership.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,167 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-031146 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,921 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 12:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-25-004548 · ownership.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares vested in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 12:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000950170-25-004548 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 367 shares acquired under the Registrant's employee stock purchase plan on December 1, 2024 Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 12:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-078790 · ownership.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,899 Underlying: Common Stock · 25,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 12:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 25,000 | $2.08 | $52,000.00 |
DisclosureSEC source: 0000950170-24-078790 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 1,203 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 255 | $43.26 | $11,030.38 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,351 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,301 | $42.39 | $55,152.51 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,606 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,378 | $41.41 | $98,481.30 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,907 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · derivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2034-02-28 F6 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,285 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 18:17 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-23-025989 · ownership.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 18:17 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000950170-23-025989 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 314 | $31.40 | $9,858.75 |
DisclosureSEC source: 0000899243-23-006979 · doc4.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,568 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,056 | $30.88 | $32,606.53 |
DisclosureSEC source: 0000899243-23-006979 · doc4.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,882 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 142,500 | $0.00 Strike: $32.07 | $0.00 |
DisclosureSEC source: 0000899243-23-006979 · doc4.xml · derivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 142,500 shares Expires 2033-02-28 F6 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 23,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006979 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,938 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. F2 · balance_after: This number includes 909 shares acquired under the Registrant's employee stock purchase plan on December 1, 2022. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 12:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-033996 · doc4.xml · derivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,899 Underlying: Common Stock · 10,000 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 12:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-22-033996 · doc4.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.